Literature DB >> 24571671

Treatment of the acute sickle cell vaso-occlusive crisis in the Emergency Department: a Brazilian method of switching from intravenous to oral morphine.

Jessica Campos1, Clarisse Lobo, Ana Maria Mach Queiroz, Emilia Matos do Nascimento, Carlos Bernardo Lima, Gilberto Cardoso, Samir K Ballas.   

Abstract

OBJECTIVES: Describe the treatment of patients with vaso-occlusive crises (VOC) in a Brazilian emergency department (ED) and the successful switch from intravenous to oral morphine. PATIENTS AND METHODS: We analyzed records of 315 patients with sickle cell disease using two different protocols for pain: one in March 2010 prescribing intravenous morphine every 4 h throughout their stay, and another in March 2011 and 2012 prescribing one initial dose of intravenous morphine followed by equianalgesic doses of oral morphine every 4 h. Patients were triaged into three groups: mild, moderate, and severe VOC. The mild group was treated within 1 h after triage, the moderate within 30 min and the severe was treated immediately. Patients whose pain was not relieved within 6 h after the first dose of morphine were transferred into a different holding area of the ED where they continued to receive the same treatment for 48 h after which they were hospitalized if still in pain.
RESULTS: The number of patients who stayed <24 h in the ED increased significantly from 63 in 2010 to 87 in 2012, and the number of admissions decreased from 26 in 2010 to 10 in 2012. The incidence of acute chest syndrome decreased from 8.5% in 2010 to 1.9% in 2012.
CONCLUSION: Patients treated with oral morphine stayed a shorter time in the ED, had more pain relief, were admitted less frequently, and had less acute chest syndrome. These differences may be due to environmental, cultural, psychological, and pharmacogenetic factors.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  intravenous morphine; oral morphine; sickle cell disease; sickle cell pain; vaso-occlusive crisis

Mesh:

Substances:

Year:  2014        PMID: 24571671     DOI: 10.1111/ejh.12293

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  6 in total

Review 1.  State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease.

Authors:  Latika Puri; Kerri A Nottage; Jane S Hankins; Doralina L Anghelescu
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

2.  Emergency Department (ED), ED Observation, Day Hospital, and Hospital Admissions for Adults with Sickle Cell Disease.

Authors:  David M Cline; Susan Silva; Caroline E Freiermuth; Victoria Thornton; Paula Tanabe
Journal:  West J Emerg Med       Date:  2018-02-12

3.  Oral morphine protocol evaluation for the treatment of vaso-occlusive crisis in paediatric sickle cell patients.

Authors:  Hugo Paquin; Evelyne D Trottier; Nancy Robitaille; Yves Pastore; Marie-Joelle Dore Bergeron; Benoit Bailey
Journal:  Paediatr Child Health       Date:  2018-05-31       Impact factor: 2.253

4.  Evaluation of a clinical protocol using intranasal fentanyl for treatment of vaso-occlusive crisis in sickle cell patients in the emergency department.

Authors:  Hugo Paquin; Evelyne D Trottier; Yves Pastore; Nancy Robitaille; Marie-Joelle Dore Bergeron; Benoit Bailey
Journal:  Paediatr Child Health       Date:  2019-03-07       Impact factor: 2.253

5.  Stiffening of sickle cell trait red blood cells under simulated strenuous exercise conditions.

Authors:  Zhensong Xu; Yi Zheng; Xian Wang; Nadine Shehata; Chen Wang; Shaorong Xie; Yu Sun
Journal:  Microsyst Nanoeng       Date:  2016-11-07       Impact factor: 7.127

6.  Factors Influencing Motivation and Engagement in Mobile Health Among Patients With Sickle Cell Disease in Low-Prevalence, High-Income Countries: Qualitative Exploration of Patient Requirements.

Authors:  David-Zacharie Issom; André Henriksen; Ashenafi Zebene Woldaregay; Jessica Rochat; Christian Lovis; Gunnar Hartvigsen
Journal:  JMIR Hum Factors       Date:  2020-03-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.